TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01620255
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo delivered subcutaneous injection, 3 doses separated by 4 weeks
Study: NCT01620255
Drug: PF-00547659 SC Injection
Normalized name: taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug Dose Level 1 delivered subcutaneous injection, 3 doses separated by 4 weeks
Study: NCT01620255
Drug: PF-00547659 SC Injection
Normalized name: taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug Dose Level 2 delivered subcutaneous injection, 3 doses separated by 4 weeks
Study: NCT01620255
Drug: PF-00547659 SC Injection
Normalized name: taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug Dose Level 3 delivered subcutaneous injection, 3 doses separated by 4 weeks
Study: NCT01620255
Drug: PF-00547659 SC Injection
Normalized name: taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug Dose Level 4 delivered subcutaneous injection, 3 doses separated by 4 weeks
Study: NCT03808922
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nebulized qd x 7 OR 10 days
Study: NCT03808922
Drug: DAS181 COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAS181 4.5mg nebulized q12h/day x 7 OR 10 days
Study: NCT04207060
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One capsule of 50 mg of indomethacin will be taken orally twice a day for a total of 28 days.
Study: NCT04207060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule of lactose not containing active study drug will be taken orally twice a day for a total of 28 days.
Study: NCT01452919
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04085757
Drug: long interval dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A small envelope including two labeled plastic bags (A \& B) (each bag containing either 1 dinoprostone tablet(3mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In long interval dinoprostone group, bag (A) contains dinoprostone tablet and bag (B) contains placebo tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
Study: NCT04085757
Drug: short interval dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A small envelope including two labeled plastic bags (A\& B) (each bag containing either 1 dinoprostone tablet(3 mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In short interval dinoprostone group, bag (A) contains placebo tablet and bag (B) contains dinoprostone tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
Study: NCT03082092
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% intravenous saline (2.1ml) intravenously on induction of total knee replacement
Study: NCT03269058
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of Dapagliflozin per day per os
Study: NCT03100058
Drug: LIK066
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIK066 will be supplied in different doses as tablets to be taken orally.
Study: NCT03100058
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00516958
Drug: Topical Dermacyn
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Dermacyn once a day for 10 Days
Study: NCT01875172
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00849719
Drug: PCA MO only
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: When visual analog scale \[VAS\] exeeds 5/10, and after the PACU drug-blinded attending physician had established that the patient is coherent and cooperative, a PCA system will be connected to the patient's IV line. The physician will start device, and deliver the first bolus. The subsequent drug boluses will be self-administered by the patient. Group 2 will be administered with only boluses of 1.5 mg/bolus of MO, by request. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
Study: NCT00439725
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients allocated to placebo will receive a matching placebo tablet once daily.
Study: NCT04181957
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants take one dose of placebo (lactose) tablet.
Study: NCT03616509
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 months on placebo, sodium chloride 0,9% injections
Study: NCT05267977
Drug: Cephalosporin 1St Generation
Normalized name: CEPHALOSPORIN 1ST GENERATION
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05267977
Drug: Aminoglycosides
Normalized name: AMINOGLYCOSIDES
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02467582
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02867839
Drug: S-1 only
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 cycles of adjuvant chemotherapy with S-1 only
Study: NCT00905138
Drug: GLPG0259
Approvals — FDA: no, EMA: no, PMDA: no
Description: single ascending doses, oral solution
Study: NCT00905138
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, oral solution
Study: NCT00905138
Drug: GLPG0259
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, oral solution, 5 days
Study: NCT00905138
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solution, 5 days
Study: NCT01400555
Drug: Cohort 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 750 mg/day + prednisone 10 mg/day
Study: NCT01400555
Drug: Cohort 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 1000 mg/day + prednisone 10 mg/day
Study: NCT01400555
Drug: Cohort 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
Study: NCT01400555
Drug: Cohort 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 60 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
Study: NCT01432457
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg and 100 mg placebo matching tablets taken orally once daily for 8 weeks; 1 week of placebo taper
Study: NCT03869034
Drug: HAIC
Normalized name: Hepatic Arterial Infusion Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX-HAIC: oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3, for maximally 8 cycles, and the safety parameters are reviewed before the start of each course of HAIC treatment. Patients who achieve partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and are assessed as eligible for R0 resection go on to undergo surgical resection. No other anti-tumor therapies are allowed before PD or postoperative relapse is confirmed.
Study: NCT04465890
Drug: ASC22
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg/1ml/1bottle
Study: NCT01645410
Drug: Atorvastatin Calcium Tablets, 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
Study: NCT03278106
Drug: Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03746275
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 - 100 mg once daily according to local label
Study: NCT03422354
Drug: General Aneasthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General Aneasthesia
Study: NCT00935194
Drug: chinese medicinal herbs
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200ml,p.o,qid,for 5 days
Study: NCT00121277
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01843634
Drug: ODSH
Normalized name: Octasulfated Disaccharide Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03510910
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen 600 mg to be taken every 8 hours (TID)
Study: NCT04295538
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion; Intravenous (IV)
Study: NCT00982254
Drug: regular human insulin
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection of 15 U regular human insulin; single dose administration on one separate dosing visit.
Study: NCT03936062
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2nd generation sulfonylurea dispensing claim is used as the reference
Study: NCT00069862
Drug: desferoxamine (DFO)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01679353
Drug: normal saline 0.5ml
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04147650
Drug: 0.10% VOS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
Study: NCT04147650
Drug: 0.20% VOS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
Study: NCT03263572
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intrathecally via spinal tap
Study: NCT02019589
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02376075
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intake of Placebo, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks
Study: NCT05058118
Drug: FL058
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg、250mg、500mg、1000mg、1500mg、2000mg
Study: NCT05058118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: empty bottle
Study: NCT03097211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules. Orally, with 240 mL of potable water.
Study: NCT03097211
Drug: BIA 6-512
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 75 mg, 100 mg. Orally, with 240 mL of potable water.
Study: NCT03097211
Drug: Madopar® 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/benserazide immediate release tablets 200mg/50mg. Orally, with 240 mL of potable water.
Study: NCT02728245
Drug: Placebo drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 table po qd
Study: NCT00510744
Drug: pancreatic enzyme supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 caps with meals, 2 with snacks
Study: NCT02153788
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03575962
Drug: GSK3640254 bis-hydrochloride salt capsule
Normalized name: bile salts Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally (as single dose) on morning of Day 1, as 2 capsules of 100 mg following a moderate calorie and fat meal during Period 1 and Period 2, at the specified sequence, as per study.
Study: NCT00878384
Drug: Medication to control ventricular rate in AF
Normalized name: Canesten AF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmacologic rate control. Current therapy will be adjusted to achieve rate-control targets of \<80bpm and \<110bpm on exercise (6 minute walk). Where necessary, additional medication will be given as per standard practice (digoxin or beta-blocker). Typical does: Digoxin 62.5-250mcg o.d. ; Bisoprolol 1.25-20mg o.d.; Carvedilol 3.125-50mg b.d. ; Nebivolol 1.25-10mg o.d.
Study: NCT00269854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be adminstered at Week 0, 2 and 6.
Study: NCT00049517
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01354808
Drug: Dual Anti-Platelet Therapy (DAPT)
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Loading: aspirin 300mg + clopidogrel 600mg~* Maintenance: aspirin 200mg/d + clopidogrel 75mg/d for 1 month
Study: NCT01354808
Drug: Triple Anti-Platelet Therapy (TAPT)
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Loading: cilostazol 200mg + aspirin 300mg + clopidogrel 600mg~* Maintenance: cilostazol 100mg bid+ aspirin 200mg/d+ clopidogrel 75mg/d for 1 month
Study: NCT03678987
Drug: mycophenolic acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will ingest mycophenolic acid as prescribed by their physician under the surveillance of an investigator.
Study: NCT01106287
Drug: MK-0941
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 60, 80, 100, 120 or 140 mg oral dose of MK-0941 will be administered in each period
Study: NCT01106287
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single oral placebo will be administered in the designated period (Periods 1-5)
Study: NCT04487574
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Placebo 2 times a day during 14 days
Study: NCT00424866
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle: 0 µg/kg
Study: NCT03242551
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC followed by T Chemotherapy with or without trastuzumab, i.e. Epirubicin 100mg/m2 and cyclophosphamine 600mg/m2 for four cycles followed by paclitaxol 175mg/m2 for four cycles with (for patients with positive HER-2) or without Trastuzumab (loading dose of 6 mg/kg followed by 4 mg/kg every 2 weeks for four cycles), each cycle is 14 days.
Study: NCT01776424
Drug: Aspirin placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin matching placebo, once daily, oral
Study: NCT04476043
Drug: INCB054707
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral; Tablet
Study: NCT04476043
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral; Tablet
Study: NCT00364091
Drug: R89674 0.025% ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03916081
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive vehicle cream matched to roflumilast cream for topical application.
Study: NCT02452450
Drug: Ibuprofen Acid
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02452450
Drug: Ibuprofen Sodium
Normalized name: Ibuprofen sodium
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00903045
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo twice a day
Study: NCT00950430
Drug: F-18 FDG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.
Study: NCT02817633
Drug: TSR-033
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSR-033 will be administered.
Study: NCT02161510
Drug: MK-2248
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-2248 in once-daily oral doses of 200-≤800 mg for 7 days
Study: NCT01743729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Lifitegrast Ophthalmic Solution 5.0%
Study: NCT00049114
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00049114
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01414777
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo or ondansetron 8mg IV will be administered prior to placement of the spinal anesthetic
Study: NCT00198952
Drug: DietPro
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00198952
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00790218
Drug: CF102
Normalized name: Cannabinoid Receptor Agonist CF102
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF102 capsules twice daily by mouth
Study: NCT00398320
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 850 mg/m2 by mouth twice a day for days 1-14 oa a 21 day cycle
Study: NCT01740323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily placebo for 6 weeks
Study: NCT01332695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match
Study: NCT02496520
Drug: Chemotherapy as needed by the patient´s tumor and stage
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01137526
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take study drug once daily for 12 weeks
Study: NCT00234169
Drug: VTP195183
Approvals — FDA: no, EMA: no, PMDA: no
Description: VTP195183: 60mg/m2 orally daily G-CSF: 10mcg/kg/day subcutaneously Provision is made for dose reduction of VTP195183 in the event of unexpected dose-limiting toxicities G-CSF10mcg/kg/day will commence on day 1 and will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first.~Patients will be treated with VTP195183 alone at 60mg/m2/day from day 1 to day 7. On day 8 VTP195183 will be continued and G-CSF10mcg/kg/day will be added. VTP195183 plus G-CSF will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first.
Study: NCT02183233
Drug: Eschscholtzia Californica
Normalized name: Eschscholzia californica extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183233
Drug: Eschscholtzia Californica Placebo
Normalized name: Eschscholzia californica extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03364309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02700828
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 \* 0,5 mg/kg /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
Study: NCT02700828
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 \* 2 ml isotonic sodium chloride solution /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
Study: NCT02394834
Drug: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Study: NCT02394834
Drug: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Study: NCT00516165
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pills taken daily in a 42-day cycle (6 weeks). Cycles will be repeated every 42 days
Study: NCT02464722
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mcg/kg iv loading dose of remifentanil over a period of 10 minutes. Later, an infusion was started at the rate of 0.4-0.8mcg/kg/min.
Study: NCT02464722
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.
Study: NCT00258323
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2/d IV continuous infusion x 4 days
Study: NCT01789203
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized 2:1 placebo comparator to active comparator, Cipro.
Study: NCT03676140
Drug: Azithromycin on Day 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 1
Study: NCT03676140
Drug: Azithromycin on Day 8
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 8
Study: NCT02028884
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
Study: NCT02922179
Drug: Long- and intermediate- acting insulins
Normalized name: Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: alone or in combination with metformin, short-acting insulin, or second-generation sulfonylurea
Study: NCT02465203
Drug: Previous treatment in DEB025 study
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up after DEB025 active study